Terms: = Prostate cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Treatment
100 results:
1. MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC.
Wang Y; Chen J; Gong L; Wang Y; Siltari A; Lou YR; Murtola TJ; Gao S; Gao Y
J Nanobiotechnology; 2024 Apr; 22(1):145. PubMed ID: 38566211
[TBL] [Abstract] [Full Text] [Related]
2. A novel exosome based therapeutic intervention against neuroendocrine prostate cancer.
Saini S; Sreekumar A; Nathani S; Asante DM; Simmons MN
Sci Rep; 2024 Feb; 14(1):2816. PubMed ID: 38307935
[TBL] [Abstract] [Full Text] [Related]
3. DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via ezh2/PRC2.
Kaarijärvi R; Kaljunen H; Nappi L; Fazli L; Kung SHY; Hartikainen JM; Paakinaho V; Capra J; Rilla K; Malinen M; Mäkinen PI; Ylä-Herttuala S; Zoubeidi A; Wang Y; Gleave ME; Hiltunen M; Ketola K
Commun Biol; 2024 Jan; 7(1):108. PubMed ID: 38238517
[TBL] [Abstract] [Full Text] [Related]
4. treatment-related Neuroendocrine prostate Carcinoma-Diagnostic and Molecular Correlates.
Gopalan A
Adv Anat Pathol; 2024 Mar; 31(2):70-79. PubMed ID: 38223983
[TBL] [Abstract] [Full Text] [Related]
5. ezh2 as a potential therapeutic target for gastrointestinal cancers.
Hashemi M; Nazdari N; Gholamiyan G; Paskeh MDA; Jafari AM; Nemati F; Khodaei E; Abyari G; Behdadfar N; Raei B; Raesi R; Nabavi N; Hu P; Rashidi M; Taheriazam A; Entezari M
Pathol Res Pract; 2024 Jan; 253():154988. PubMed ID: 38118215
[TBL] [Abstract] [Full Text] [Related]
6. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (ezh2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract] [Full Text] [Related]
7. Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Govindan S; Cheranda N; Riekhof F; Luo S; Schoen MW
Prostate; 2024 Feb; 84(3):245-253. PubMed ID: 37909677
[TBL] [Abstract] [Full Text] [Related]
8. Downregulation of ezh2 inhibits epithelial-mesenchymal transition in enzalutamide-resistant prostate cancer.
Zhang Z; Wang X; Kim M; He D; Wang C; Fong KW; Liu X
Prostate; 2023 Nov; 83(15):1458-1469. PubMed ID: 37475584
[TBL] [Abstract] [Full Text] [Related]
9. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.
Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY
Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903
[TBL] [Abstract] [Full Text] [Related]
10. Beyond Expression: Role of Phosphorylated Residues of ezh2 in Lineage Plasticity in prostate cancer.
Nouruzi S; Tabrizian N; Zoubeidi A
Endocrinology; 2023 Feb; 164(4):. PubMed ID: 36718085
[TBL] [Abstract] [Full Text] [Related]
11. Simultaneous administration of ezh2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells.
Negri A; Marozzi M; Trisciuoglio D; Rotili D; Mai A; Rizzi F
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2163242. PubMed ID: 36629431
[TBL] [Abstract] [Full Text] [Related]
12. A cryptic transactivation domain of ezh2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation.
Wang J; Park KS; Yu X; Gong W; Earp HS; Wang GG; Jin J; Cai L
Nucleic Acids Res; 2022 Oct; 50(19):10929-10946. PubMed ID: 36300627
[TBL] [Abstract] [Full Text] [Related]
13. Dual-Acting Peptides Target ezh2 and AR: A New Paradigm for Effective treatment of Castration-Resistant prostate cancer.
Han Z; Rimal U; Khatiwada P; Brandman J; Zhou J; Hussain M; Viola RE; Shemshedini L
Endocrinology; 2022 Nov; 164(1):. PubMed ID: 36288553
[TBL] [Abstract] [Full Text] [Related]
14. DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing ezh2 stability.
Li Z; Li B; Yu H; Wang P; Wang W; Hou P; Li M; Chu S; Zheng J; Mao L; Bai J
Oncogene; 2022 Aug; 41(33):3991-4002. PubMed ID: 35804015
[TBL] [Abstract] [Full Text] [Related]
15. Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/ezh2/ androgen receptor signaling pathway.
Chen X; Yang G; Liu M; Quan Z; Wang L; Luo C; Wu X; Zheng Y
Biochem Biophys Res Commun; 2022 Jul; 613():53-60. PubMed ID: 35533600
[TBL] [Abstract] [Full Text] [Related]
16. Prediction of recurrence from metabolites and expression of TOP2A and ezh2 in prostate cancer patients treated with radiotherapy.
Hansen AF; Høiem TS; Selnaes KM; Bofin AM; Størkersen Ø; Bertilsson H; Wright AJ; Giskeødegård GF; Bathen TF; Rye MB; Tessem MB
NMR Biomed; 2023 May; 36(5):e4694. PubMed ID: 35032074
[TBL] [Abstract] [Full Text] [Related]
17. Inhibition of ezh2 transactivation function sensitizes solid tumors to genotoxic stress.
Liao Y; Chen CH; Xiao T; de la Peña Avalos B; Dray EV; Cai C; Gao S; Shah N; Zhang Z; Feit A; Xue P; Liu Z; Yang M; Lee JH; Xu H; Li W; Mei S; Pierre RS; Shu S; Fei T; Duarte M; Zhao J; Bradner JE; Polyak K; Kantoff PW; Long H; Balk SP; Liu XS; Brown M; Xu K
Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35031563
[TBL] [Abstract] [Full Text] [Related]
18. Extracellular Matrix in Synthetic Hydrogel-Based prostate cancer Organoids Regulate Therapeutic Response to ezh2 and DRD2 Inhibitors.
Mosquera MJ; Kim S; Bareja R; Fang Z; Cai S; Pan H; Asad M; Martin ML; Sigouros M; Rowdo FM; Ackermann S; Capuano J; Bernheim J; Cheung C; Doane A; Brady N; Singh R; Rickman DS; Prabhu V; Allen JE; Puca L; Coskun AF; Rubin MA; Beltran H; Mosquera JM; Elemento O; Singh A
Adv Mater; 2022 Jan; 34(2):e2100096. PubMed ID: 34676924
[TBL] [Abstract] [Full Text] [Related]
19. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.
Davies A; Nouruzi S; Ganguli D; Namekawa T; Thaper D; Linder S; Karaoğlanoğlu F; Omur ME; Kim S; Kobelev M; Kumar S; Sivak O; Bostock C; Bishop J; Hoogstraat M; Talal A; Stelloo S; van der Poel H; Bergman AM; Ahmed M; Fazli L; Huang H; Tilley W; Goodrich D; Feng FY; Gleave M; He HH; Hach F; Zwart W; Beltran H; Selth L; Zoubeidi A
Nat Cell Biol; 2021 Sep; 23(9):1023-1034. PubMed ID: 34489572
[TBL] [Abstract] [Full Text] [Related]
20. The Role of Tumor-related LncRNA PART1 in cancer.
Chen J; Meng E; Lin Y; Shen Y; Hu C; Zhou G; Yuan C
Curr Pharm Des; 2021; 27(40):4152-4159. PubMed ID: 34225608
[TBL] [Abstract] [Full Text] [Related]
[Next]